Menstrual regulation with prostaglandin analogues.
The development of generally applicable, simple non-surgical methods for menstrual regulation has been desired for a long time. Such an approach to fertility control depends on the availability of a suitable therapeutic agent that should be effective, reliable, simple to administer and free from disturbing side effects. The classical prostaglandins have shown the capability but are unsuitable mainly due to high incidence of side effects. Most of these drawbacks seem to be overcome when prostaglandin analogues are used; however, vaginal administration caused appreciable pain in 10-30% of women, and so severely limits self-administration of these analogues.
D000019:Abortifacient Agents / Q000008:administration & dosage*; D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage*; D000028:Abortion, Induced / Q000379:methods*; D002986:Clinical Trials as Topic; D004107:Dilatation and Curettage; D015237:Dinoprost / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D010146:Pain / Q000209:etiology; D011247:Pregnancy; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage* / Q000009:adverse effects; D011465:Prostaglandins, Synthetic / Q000008:administration & dosage* / Q000009:adverse effects; D012646:Self Administration; D013488:Suppositories; D014619:Vacuum Curettage; D014621:Vagina
D000019:Abortifacient Agents; D000020:Abortifacient Agents, Nonsteroidal; D011461:Prostaglandins F, Synthetic; D011465:Prostaglandins, Synthetic; D013488:Suppositories; C022934:16,16-dimethylprostaglandin F2alpha; D015237:Dinoprost